Biggest News Aggregation in the World
📰 Confidence Interval News

Page 37 - Confidence Interval News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Confidence Interval. Real-time updates on events, politics, business and more.

Hybrid immunity protects against infection with omicron variant of COVID-19

1. Previous infection, vaccination, and hybrid immunity protected against infection with the omicron variant of coronavirus disease 2019 (COVID-19). 2. Hybrid immunity from previous infection and recent booster vaccination provided the strongest overall protection against the omicron variant. Evidence Rating Level: 1 (Excellent) Study Rundown: The omicron variant of SARS-CoV-2 was prevalent from late 2021
World Health Organization Rating Level Inferring Intrinsic Severity Confidence Interval

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumo

–Phase 2 trial showed chemotherapy-free TUKYSA combination resulted in clinically meaningful and durable tumor responses––Results presented in late-breaking oral session at the ESMO World Congress on Gastrointestinal Cancer–BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced full results from...
United Kingdom United States Comunidad Autonoma De Cataluna David Caouette Roger Dansey Peggy Pinkston

Seagen Inc.: Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer

-Phase 2 trial showed chemotherapy-free TUKYSA combination resulted in clinically meaningful and durable tumor responses- -Results presented in late-breaking oral session at the ESMO World Congress
United Kingdom United States Comunidad Autonoma De Cataluna David Caouette Roger Dansey Peggy Pinkston

Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA® (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer - Press Release

–Phase 2 trial showed chemotherapy-free TUKYSA combination resulted in clinically meaningful and durable tumor responses– –Results presented in late-b
Comunidad Autonoma De Cataluna Roger Dansey Johnh Strickler Duke University School Of Medicine Approval Program World Congress On Gastrointestinal Cancer

Factors associated with uptake of contraceptives among HIV positive women on dolutegravir based anti-retroviral treatment-a cross sectional survey in urban Uganda | BMC Women's Health

In May 2018, following the preliminary results of a study in Botswana that reported congenital anomalies in babies born to HIV-positive women taking dolutegravir drug, the WHO issued a teratogenicity alert. However, there are scarce data on the impact of this guidance on contraceptive uptake among women taking dolutegravir. We assessed the uptake of contraceptives in HIV-positive women of reproductive age on dolutegravir regimens. We conducted a cross-sectional survey from April 2019 to July 201...
Kampala Capital City Kampala Capital City Authority Infectious Diseases Institute Confidence Interval

A Mother's Blood May Carry the Secret to One Type of Autism

Maternal autoantibody–related autism spectrum disorder (MAR ASD) is marked by specific maternal antibodies that react to certain proteins in the fetal brain. Examining the plasma of expecting mothers, researchers found mothers with reactivity to one of the nine MAR ASD patterns were eight times as likely to have a child diagnosed with autism.
United States Robert Yolken Joseph Schauer Cathleen Yoshida Lisa Croen Robin Hansen

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science